Publications by authors named "L Singerman"
Article Synopsis
- Imaging, particularly multi-detector CT, is essential for quickly assessing trauma patients, especially those with moderate to severe injuries.
- While some strategies for using whole-body CT are widely accepted, there are still debates regarding its application and interpretation in certain cases.
- Timely diagnosis is critical, as delays can harm patient outcomes; therefore, understanding imaging tools and recognizing potential errors is vital to prevent unnecessary procedures.
Objective: Retrospective, real-world study to evaluate visual acuity (VA), anti-vascular endothelial growth factor (anti-VEGF) injection intervals, and central macular thickness (CMT) in neovascular age-related macular degeneration (nAMD) eyes switched to brolucizumab only or to brolucizumab alternating with another anti-VEGF.
Methods: The overall study population comprised eyes that were given ≥1 brolucizumab injection between 1 October 2019 and 30 November 2021. The brolucizumab-only (BRO) cohort consisted of prior anti-VEGF-treated eyes treated exclusively with ≥3 brolucizumab injections over ≥12 or ≥18 months; the alternating brolucizumab (ALT) cohort comprised prior anti-VEGF-treated eyes treated with ≥2 brolucizumab injections and ≥1 other anti-VEGF over ≥12 or ≥18 months.
Background: The anti-vascular endothelial growth factor (anti-VEGF) injection interval influences treatment burden and compliance in neovascular age-related macular degeneration (nAMD). This real-world study investigates visual acuity (VA), injection-interval extension, central macular thickness (CMT) and safety in nAMD eyes switched to the anti-VEGF agent brolucizumab and followed for up to 18 months.
Methods: This retrospective study included patients with nAMD who were switched from other anti-VEGF agents to brolucizumab only.
Purpose: The purpose of this study was to determine if a mobile application, the Checkup Vision Assessment System, could reliably monitor visual acuity (VA) and metamorphopsia remotely versus standard VA reference tests in the clinic. With the current COVID-19 pandemic, an even greater need for remote monitoring exists. Mobile tools enhance the ability to monitor patients virtually by enabling remote monitoring of VA and Amsler grid findings.
View Article and Find Full Text PDFPurpose: To establish a process to evaluate and standardize a state-of-the-art nomenclature for reporting neovascular age-related macular degeneration (AMD) data.
Design: Consensus meeting.
Participants: An international panel of retina specialists, imaging and image reading center experts, and ocular pathologists.